Benjamin Resio, MD
Assistant ProfessorAbout
Research
Publications
2026
Response to neoadjuvant chemoimmunotherapy in EGFR- or ALK-mutated non-small cell lung cancer.
Caturegli G, Jernigan E, Canavan M, Lynch A, Patil J, Resio B, Boffa D. Response to neoadjuvant chemoimmunotherapy in EGFR- or ALK-mutated non-small cell lung cancer. Journal Of Clinical Oncology 2026, 44: 8054-8054. DOI: 10.1200/jco.2026.44.16_suppl.8054.Peer-Reviewed Original ResearchWild-type patientsNeoadjuvant chemoimmunotherapyNodal downstagingLung cancerALK mutationsStage I-III NSCLCTreated with neoadjuvant chemoimmunotherapyNon-small cell lung cancerMutation-targeted therapiesCharlson-Deyo scoreComplete pathologic responsePathological complete responseHigh tumor gradeCell lung cancerYear of diagnosisAssociated with significantly higher oddsRate of pCRLack of efficacyMultivariate logistic regressionSignificantly higher oddsEGFR/ALK mutationsKIF5B-ALKNeoadjuvant immunotherapyTFG-ALKPCR rateA risk stratification schema for patients with non–small cell lung cancer with multiple organ metastases.
Esnaola G, Wang M, Resio B, Pan A, Lee D, Cohen A, Kaur M, Schmitter M, Ishizuka J, Olino K. A risk stratification schema for patients with non–small cell lung cancer with multiple organ metastases. Journal Of Clinical Oncology 2026, 44: 11138-11138. DOI: 10.1200/jco.2026.44.16_suppl.11138.Peer-Reviewed Original ResearchNon-small cell lung cancerPattern of metastasisSite of metastasisCell lung cancerMultiple organ sitesMetastatic sitesTargeted therapySystemic therapyPrognostic valueLung cancerMetastatic non-small cell lung cancerOrgan sites of metastasesTime to next therapyResponse to systemic therapyClustering of metastasesIndividual organ sitesMultiple organ metastasesReal-world patternsKaplan Meier methodSite of diseaseDatabase of patientsRisk stratification schemaPoor overall survivalInclusion of patientsEGFR mutationsDrivers of organotropism and patterns of metastatic progression in metastatic non–small cell lung cancer.
Esnaola G, Resio B, Pan A, Lee D, Cohen A, Wang M, Schmitter M, Ishizuka J, Olino K. Drivers of organotropism and patterns of metastatic progression in metastatic non–small cell lung cancer. Journal Of Clinical Oncology 2026, 44: e20541-e20541. DOI: 10.1200/jco.2026.44.16_suppl.e20541.Peer-Reviewed Original ResearchNon-small cell lung cancerReal-world overall survivalCell lung cancerOrgan sitesSystemic therapyPrognostic valueMetastatic progressionAdvanced non-small cell lung cancerFollow-upLung cancerMedian real-world overall survivalMetastatic non-small cell lung cancerMetastatic potentialOrgan-specific spreadPattern of metastasisDistant lymph nodesKaplan Meier methodDistant organ sitesDistribution of metastasesPhenotype of patientsInterferon-gamma responsesSite-specific diseaseClinico-genomic databaseMetastatic diagnosisOverall survivalRF79. Radiographic Tumor Regression as a Predictor for Pathologic Response after Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Bader J, De Santis W, Ermer T, Kramer R, Boffa D, Blasberg J, Resio B, Bader A, Dacic S, Woodard G. RF79. Radiographic Tumor Regression as a Predictor for Pathologic Response after Neoadjuvant Therapy for Non-Small Cell Lung Cancer. Journal Of Thoracic And Cardiovascular Surgery 2026, 171: s164. DOI: 10.1016/j.jtcvs.2026.03.527.Peer-Reviewed Original ResearchRadiographic Tumor Regression as a Predictor for Pathologic Response after Neoadjuvant Therapy for Non-Small Cell Lung Cancer
Bader J, Ermer T, de Santis W, Ragoowansi H, Kramer R, Zolfaghari E, Tremblay E, Resio B, Boffa D, Blasberg J, Bader A, Dacic S, Woodard G. Radiographic Tumor Regression as a Predictor for Pathologic Response after Neoadjuvant Therapy for Non-Small Cell Lung Cancer. JTCVS Open 2026, 101831. DOI: 10.1016/j.xjon.2026.101831.Peer-Reviewed Original ResearchPathological complete responseNon-small cell lung cancerNeoadjuvant therapyCell lung cancerPathological responseViable tumorTumor sizeLung cancerPathologic response to neoadjuvant therapyPatients treated with neoadjuvant therapyAssociated with pathologic complete responseResponse to neoadjuvant therapyPD-L1 statusPersistent viable tumorRadiographic tumor regressionRadiographic tumor responseRadiographic tumor sizeResidual viable tumorLong-term outcomesPET SUVmaxSUVmax decreaseComplete responseNeoadjuvant treatmentRadiographic responsePD-L1RF77. The Prognosis of Single-site Oligometastatic Non-Small Cell Lung Cancer Treated with Local Therapies in the Era of Immunotherapy
Esnaola G, Canavan M, Caturegli G, Lynch A, Resio B. RF77. The Prognosis of Single-site Oligometastatic Non-Small Cell Lung Cancer Treated with Local Therapies in the Era of Immunotherapy. Journal Of Thoracic And Cardiovascular Surgery 2026, 171: s162-s163. DOI: 10.1016/j.jtcvs.2026.03.525.Peer-Reviewed Original ResearchReal-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer
Caturegli G, Canavan M, Ayoade O, Boffa D, Resio B. Real-World Outcomes of Radiation After Chemoimmunotherapy for Stage III Lung Cancer. Clinical Lung Cancer 2026, 27: 48-54.e2. PMID: 42070908, DOI: 10.1016/j.cllc.2026.03.016.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerStage III non-small cell lung cancerIII non-small cell lung cancerStage III NSCLC patientsThree-year overall survivalIII NSCLC patientsStage III patientsOutcome of radiationOverall survivalNSCLC patientsIII patientsRadiation patientsNonsurgical optionsLung cancerClinical stage III patientsStage III lung cancerIII lung cancerNational Cancer DatabaseReal-world outcomesCell lung cancerKaplan-Meier curvesStandard treatment approachTotal radiation doseAlternative nonsurgical optionNeoadjuvant chemoimmunotherapyUse of Complementary and Alternative Medicine in the Management of Breast Cancer
Ayoade O, Caturegli G, Canavan M, Resio B, Berger E, Boffa D. Use of Complementary and Alternative Medicine in the Management of Breast Cancer. JAMA Network Open 2026, 9: e260337. PMID: 41770560, PMCID: PMC12954545, DOI: 10.1001/jamanetworkopen.2026.0337.Peer-Reviewed Original ResearchConceptsCohort studyManagement of breast cancerBreast cancerCohort study of dataMedical management of breast cancerTreated with CAMCox proportional hazards modelsMedical managementYear of diagnosisFemale patientsCombination of CAMProportional hazards modelTraditional therapiesAlternative medicineStudy of dataMain OutcomesEndocrine therapyNo treatmentCharlson Comorbidity IndexInsurance typeNonmedical personnelPrimary outcomeFacility typeSurvival timeHazards model
2025
Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer
Caturegli G, Kaminski M, Canavan M, Ayoade O, Resio B, Boffa D. Real-world perioperative outcomes of neoadjuvant chemoimmunotherapy in non–small cell lung cancer. JTCVS Open 2025, 28: 554-564. PMID: 41473080, PMCID: PMC12745116, DOI: 10.1016/j.xjon.2025.09.016.Peer-Reviewed Original ResearchNon-small cell lung cancerPathological complete responseNational Cancer DatabaseNeoadjuvant chemoimmunotherapyCell lung cancerChemoimmunotherapy patientsNeoadjuvant chemoradiotherapyPerioperative outcomesStage I to III non-small cell lung cancerIII non-small cell lung cancerLung cancerTreated with neoadjuvant chemoimmunotherapyNon-small cell lung cancer recurrenceOutcome of immunotherapyPeri-operative outcomesMethods Adult patientsInduction chemoimmunotherapyComplete responseNeoadjuvant chemotherapyNodal downstagingPerioperative therapyCancer DatabasePneumonectomy rateChemoimmunotherapyAdult patientsMortality Risk and Cause of Death Associated With Removal of the Adult Thymus: Analysis of the U.S. Thymoma Population
Resio B, Canavan M, Caturegli G, Detterbeck F, Boffa D. Mortality Risk and Cause of Death Associated With Removal of the Adult Thymus: Analysis of the U.S. Thymoma Population. Journal Of Thoracic Oncology 2025, 21: 186-194. PMID: 40865907, DOI: 10.1016/j.jtho.2025.08.017.Peer-Reviewed Original ResearchSurveillance Epidemiology and End ResultsNational Cancer DatabaseDuctal carcinoma in situPropensity-matched patientsThyroid cancerAdult thymusU.S. populationImmunologic end pointsCarcinoma in situFive-year survivalCancer incidencePartial thymectomyThyroid lobectomyResected breastLonger-term outcomesPartial mastectomyThyroid neoplasmsTotal thymectomyCancer DatabaseCause of deathNo significant differenceSecondary cancersSmall thymomaThymectomyEnd Results
Clinical Care
Overview
Benjamin Resio, MD, is a thoracic surgeon who treats the entire spectrum of thoracic surgical diseases. He has a special interest in thoracic surgical oncology, multidisciplinary care for lung and esophageal cancer, and minimally invasive and robotic surgery. Dr. Resio cares for patients as part of the Center for Thoracic Cancers at Smilow Cancer Hospital.
Also an assistant professor of surgery at Yale School of Medicine, Dr. Resio received his medical degree with honors from Dartmouth Medical School, where he was elected to the Alpha Omega Alpha honor society. He completed his residency at Yale School of Medicine, followed by a fellowship in cardiothoracic surgery at Memorial Sloan Kettering Cancer Center.
Clinical Specialties
Thoracic Surgery
Yale Medicine News
News
Get In Touch
Contacts
Appointment Number
Locations
Patient Care Locations
Are You a Patient? View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.